Eli Lilly and Co. has opened its new Biotechnology Center in San Diego, as part of its strategy to develop more biopharmaceuticals. The center will focus on discovering, engineering and conducting Phase I and II trials on potential biologic medicines, with an emphasis on cancer, diabetes and autoimmune diseases. “We are moving full speed ahead toward building a biotechnology powerhouse,” said John Lechleiter, Ph.D., Lilly chairman and chief executive officer. “The science, t...